Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

35 min ago | Pharmaceutical Processing

FDA Approves Gilead Sciences Drug for Three Cancers

The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Cancer, Health, Startups, Leukemia, Lymphoma

5 hrs ago | Seeking Alpha

Gilead Earnings Preview: Non-Sovaldi Sales Bogey May Be Unrealistic

Gilead Sciences, Inc. reports Q2 earnings tomorrow. Gilead is a biopharmaceutical company that develops and markets medicines for unmet needs.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Hepatitis, Health, Pharmaceuticals, Pharmasset

Tue Jul 22, 2014

Bloomberg

Doctors' Dilemma: Who Gets Costly Cure for Deadly Virus

Early this year, liver specialist Ken Flora and his colleagues sent letters to 1,300 patients announcing exciting news: powerful new drugs to cure the lethal hepatitis C virus were finally available.

Comment?

Related Topix: Medicine, Hepatitis, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, New York

SFGate

Netflix falls on lower quarterly forecast

That's how much Netflix shares dropped on Tuesday after the streaming-video company forecast a profit of 89 cents a share, falling short of the $1.02 projected by analysts.

Comment?

Related Topix: Netflix, Startups, Biotech, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, San Mateo County, CA, Foster City, CA

Mon Jul 21, 2014

Seattle Post-Intelligencer

Costly hepatitis C drugs could add $300 to every American's yearly premium, CVS says

Gilead Sciences' new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Retail, CVS, Startups, CGI Pharmaceuticals

Seeking Alpha

Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?

Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed.

Comment?

Related Topix: Biotech, Biogen Idec, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Financial Markets, Amgen

CorpWatch

Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill

Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

1 comment

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Startups, Food and Drug Administration, Liver Cancer, US News, Liberal Political News

TheStreet.com

How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding?

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Mozilla, TheStreet, Financial Markets

Fri Jul 18, 2014

Benzinga

Biotech Enters Reporting Season With Large Caps Central To Sector Performance

Biotech stock stocks enter their earnings season with investors increasingly interested in the long-term outlook for product pipelines, although large-cap growth stocks remain central to the sectors performance, an analyst said Friday.

Comment?

Related Topix: Financial Markets, Biotech, Biogen Idec, Hemophilia, Health, Medicine, Gilead Sciences, Healthcare Industry, Startups, Celgene

Insider Monkey

NASH a Big Opportunity For Gilead Sciences, Inc.

After being a dominant player in the hepatitis C market with its drug Sovaldi, Gilead Sciences, Inc. is now eyeing to monetize from the next global epidemic, NASH, or nonalcoholic steatohepatitis.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Hepatitis, Health, Epidemic, Natural Disasters

SchaeffersResearch.com

Analyst Upgrades: Microsoft Corporation, Gilead Sciences, Inc., and Amgen, Inc.

Despite the blue chip's impressive year-to-date gain of 19%, most analysts remain on the fence when it comes to Microsoft Corporation.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Amgen, Healthcare Industry, Microsoft, Startups, Day Trading, Financial Markets, Personal Finance

Thu Jul 17, 2014

SFGate

Could California spend $6.7 billion for hepatitis C drug?

This undated handout photo provided by Gilead Sciences shows the Hepatitis-C medication Sovaldi.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Medicaid, Express Scripts

SchaeffersResearch.com

Most Active Options Update: Micron Technology, Inc.

The 20 stocks listed in the table below have attracted the highest total options volume during the past 10 trading days.

Comment?

Related Topix: Semiconductors, Micron Technology, Electronics, Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Banking, JP Morgan Chase , MannKind

Wed Jul 16, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

InterGen Announces Agreement with IEnova to Close the Purchase of 50 Percent of the First Phase of the Energa Sierra Jurez Wind Project )--InterGen Announces Agreement with IEnova to Close the Purchase of 50 Percent of the First Phase of the Energia Sierra Juarez Wind Project )--Gilead Sciences, Inc. announced today that its second quarter 2014 ... (more)

Comment?

Related Topix: Gilead Sciences, Biotech, Medicine, Healthcare Industry, Startups, Mortgage, Personal Finance, Palm Beach Gardens, FL

Investor's Business Daily

Gilead Sciences to Release Second Quarter 2014 Financial Results on...

Gilead Sciences, Inc. announced today that its second quarter 2014 financial results will be released on Wednesday, July 23, at 4:05 p.m. Eastern Time.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

BioSpace

That Model Genentech, Gilead Sciences, Inc., And Amgen Were Built On - Does It Work Anymore?

"The model is broken." I used to hear that chant from biotech VCs all the time, often accompanied by the thwack of self-flagellation.

Comment?

Related Topix: Biotech, Medicine, Amgen, Gilead Sciences, Healthcare Industry, Startups

Circulation

Ranolazine Effectively Suppresses Atrial Fibrillation in the Setting...

From the Masonic Medical Research Laboratory, Utica, NY ; Department of Clinical and Biological Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY ; and Gilead Sciences, Foster City, CA .

Comment?

Related Topix: Utica, NY, Ithaca, NY, Startups

Tue Jul 15, 2014

The Washington Post

J&J's Blockbuster Hepatitis C Sales Not Enough for Investors

While Johnson & Johnson's new hepatitis C pill Olysio has had blockbuster revenue in 2014, concerns the sales surge probably won't last drove down shares.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, New Brunswick, NJ, Business News

Mon Jul 14, 2014

Business Journal

Wyden battles drug maker over hep C drug price

Oregon U.S. Sen. Ron Wyden is one of many who want to know why the price of Sovaldi is so high.

Comment?

Related Topix: US News, US Senate, Ron Wyden, Democrat, US Politics, Gilead Sciences, Biotech, Medicine, Healthcare Industry, Startups, Personal Finance, Social Security

Insider Monkey

Actavis plc (ACT), Gilead Sciences Inc. (GILD), Macquaire...

Bernard Selz 's Selz Capital recently disclosed at the SEC its long equity positions as of June 30 2014.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Financial Markets, Energy, Oil & Gas, Magellan Midstream Partners LP

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••